Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Parkinson's Disease Cell Transplantation Therapy: A New Dawn With Pluripotent Stem Cell-Based Therapy.

Journal of neurochemistry·2026
Same author

Amyloid-β1-42 oligomers compromise oligodendrocyte precursor cells and disrupt blood-brain barrier integrity in vitro.

Brain research·2026
Same author

Treatment of spinal injury muscle spasticity by spinal subpial AAV9-GAD65/VGAT delivery: An efficacy and safety study in rat, pig, and NHP.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Evaluation of a commercial AI-assisted cell counting software for dopaminergic neurons across species.

PloS one·2026
Same author

Peptide Substitutes of PEG: Biological Outcomes on Prospective Lipid Nanoparticle Shielding Materials.

Advanced healthcare materials·2026
Same author

Association between ischemic stroke and hyperintense plaques detected by high-resolution vessel wall MRI in Japanese patients with intracranial atherosclerotic disease.

Frontiers in stroke·2026

Related Experiment Video

Updated: Jun 5, 2025

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells
10:02

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

Published on: June 10, 2022

2.1K

A lipid nanoparticle-based oligodendrocyte-specific mRNA therapy.

Masanori Sawamura1, Kiyoshi Tachikawa2, Rie Hikawa1

  • 1Department of Neurology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Molecular Therapy. Nucleic Acids
|December 6, 2024
PubMed
Summary

Researchers developed LUNAR lipid nanoparticles for efficient mRNA delivery into brain oligodendrocytes. This novel method shows promise for treating neurological disorders like Krabbe disease by targeting damaged cells.

Keywords:
Krabbe diseaseMT: Delivery Strategiesdrug delivery systemlipid nanoparticlesmRNA therapyoligodendrocyte

More Related Videos

Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA
08:29

Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA

Published on: February 1, 2019

10.0K
Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing
08:55

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing

Published on: January 20, 2023

10.9K

Related Experiment Videos

Last Updated: Jun 5, 2025

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells
10:02

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

Published on: June 10, 2022

2.1K
Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA
08:29

Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA

Published on: February 1, 2019

10.0K
Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing
08:55

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing

Published on: January 20, 2023

10.9K

Area of Science:

  • Neuroscience
  • Biotechnology
  • Gene Therapy

Background:

  • Oligodendrocytes are crucial glial cells in the brain, but efficient mRNA delivery remains a challenge.
  • Current viral vectors show limited efficiency in targeting oligodendrocytes for therapeutic interventions.

Purpose of the Study:

  • To develop a non-viral method for highly efficient and specific mRNA delivery into oligodendrocytes.
  • To evaluate the therapeutic potential of LUNAR lipid nanoparticles for treating oligodendrocyte-related neurological disorders.

Main Methods:

  • Utilized LUNAR lipid nanoparticles for mRNA delivery into oligodendrocytes.
  • Investigated the uptake mechanism of LUNAR nanoparticles, identifying low-density lipoprotein receptors and apoprotein E involvement.
  • Administered LUNAR-human galactosylceramidase mRNA to twitcher mice, a model for Krabbe disease.

Main Results:

  • Achieved high efficiency and specificity in delivering mRNA into oligodendrocytes using LUNAR nanoparticles.
  • Demonstrated that LUNAR nanoparticle uptake is mediated by low-density lipoprotein receptors in the presence of apoprotein E.
  • A single dose of LUNAR-human galactosylceramidase mRNA significantly improved disease phenotypes and survival rates in twitcher mice.

Conclusions:

  • LUNAR lipid nanoparticles represent a breakthrough for efficient mRNA delivery into oligodendrocytes.
  • This cell-specific nanocarrier approach holds significant potential for developing novel mRNA therapeutics for neurological disorders affecting oligodendrocytes.
  • The study highlights a promising strategy for treating Krabbe disease and other myelin disorders.